TAŞTEKİN, D. Et Al. 2023. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience. Journal of cancer research and therapeutics , vol.19, no.2 , 253-258.

TAŞTEKİN, D., Paksoy, N., DOĞAN, İ., Ferhatoglu, F., KHANMAMMADOV, N., Bozbey, H. U., ... KARABULUT, S.(2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience. Journal of cancer research and therapeutics , vol.19, no.2, 253-258.

TAŞTEKİN, Didem Et Al. "Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience," Journal of cancer research and therapeutics , vol.19, no.2, 253-258, 2023

TAŞTEKİN, Didem Et Al. "Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience." Journal of cancer research and therapeutics , vol.19, no.2, pp.253-258, 2023

TAŞTEKİN, D. Et Al. (2023) . "Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience." Journal of cancer research and therapeutics , vol.19, no.2, pp.253-258.

@article{article, author={Didem TAŞTEKİN Et Al. }, title={Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience}, journal={Journal of cancer research and therapeutics}, year=2023, pages={253-258} }